PDS Biotechnology Corp Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
PDS Biotechnology Corp (PDSB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -6.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-30
- PDS Biotechnology Corp effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -6.00%.
- PDS Biotechnology Corp effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.90%.
- PDS Biotechnology Corp effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.40%, a 104.49% decline from fiscal 2021.
- PDS Biotechnology Corp effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 8.90%, a 97.78% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -6.00% 10-K · filed 2026-03-30 | |
| 2023-12-31 | -0.90% 10-K · filed 2025-03-27 | |
| 2022-12-31 | -0.40% 10-K · filed 2024-03-28 | 0.40% 10-K · filed 2023-03-28 |
| 2021-12-31 | 8.90% 10-K · filed 2023-03-28 | |
| 2020-12-31 | 4.50% 10-K · filed 2022-03-31 | |
| 2019-12-31 | 4.10% 10-K · filed 2021-03-18 | |
| 2018-12-31 | 1.80% 10-K · filed 2020-03-27 | 5.40% 10-K · filed 2019-02-21 |
| 2017-12-31 | 11.00% 10-K · filed 2019-02-21 | |
| 2016-12-31 | 10.60% 10-K · filed 2018-03-01 | 10.62% 10-K · filed 2017-03-02 |
| 2015-12-31 | 5.80% 10-K · filed 2018-03-01 | -5.84% 10-K · filed 2016-03-08 |
| 2014-12-31 | 6.58% 10-K · filed 2017-03-02 | -2.96% 10-K · filed 2016-03-08 |
| 2013-12-31 | -6.58% 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |